Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01057810 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
A Phase 3 study of Prostate Cancer, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 837
- Enrollment target
- 20
- Study locations
NCT01057810 is a Phase 3 study of Prostate Cancer that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 837 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT01057810, a Phase 3 study of Prostate Cancer, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 837 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if asymptomatic or minimally symptomatic patients with metastatic prostate cancer who have not received chemotherapy live longer when treated with ipilimumab than those treated with a placebo
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ipilimumab
Study Locations (20)
Florida
- Lynn Cancer Institute Center For Hematology-Oncology - Boca Raton
- Baptist Cancer Institute - Jacksonville
- Mount Sinai Comprehensive Cancer Center - Miami Beach
- Md Anderson Cancer Center Orlando - Orlando
- Hematology Oncology Associates Of The Treasure Coast - Port Saint Lucie
California
- Desert Hematology Oncology - Rancho Mirage
- Southern California Permanente Medical Group - San Diego
- Pacific Hematology Oncology Associates - San Francisco
Georgia
- Northside Hospital - Atlanta
- Georgia Regents University - Augusta
- Gwinnett Hospital System Inc. - Lawrenceville
Arizona
- Pinnacle Oncology Hematology - Scottsdale
- Arizona Cancer Center - Tucson
Illinois
- University Of Chicago - Chicago
- Cancer Care Specialists Of Central Illinois - Decatur
Alaska
- Alaska Clinical Research Center, Llc - Anchorage
District of Columbia
- George Washington University - Washington D.C.
Hawaii
- Straub Clinic And Hospital - Honolulu
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 837 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01057810
The ClinicalTrials.gov registry entry for NCT01057810 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 837 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (38% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01057810 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT01057810 about?
NCT01057810 is a clinical study titled "Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer". The purpose of this study is to determine if asymptomatic or minimally symptomatic patients with metastatic prostate cancer who have not received chemotherapy live longer when treated with ipilimumab than those treated with a placebo
What is the current status of trial NCT01057810?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 837 participants. The study started on 2010-07. Estimated completion is 2015-07.
What conditions does trial NCT01057810 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT01057810?
The interventions under investigation include: Placebo (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT01057810?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01057810 being conducted?
This trial has 20 study locations across Alaska, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.